Related references
Note: Only part of the references are listed.Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG)
Paula Cramer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Nucleotide Excision Repair and Transcription-coupled DNA Repair Abrogate the Impact of DNA Damage on Transcription
Aditi Nadkarni et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Trabectedin: Supportive care strategies and safety profile
Karin Jordan et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
Mohammed Z. H. Farooqui et al.
LANCET ONCOLOGY (2015)
The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL
E. Vasyutina et al.
LEUKEMIA (2015)
Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden
Christian Prinz et al.
MOLECULAR CANCER (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
Peter Dreger et al.
BLOOD (2014)
Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
M. D'Incalci et al.
BRITISH JOURNAL OF CANCER (2014)
A C. elegans homolog of the Cockayne syndrome complementation group A gene
Vipin Babu et al.
DNA REPAIR (2014)
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas
Jean-Yves Blay et al.
EUROPEAN JOURNAL OF CANCER (2014)
DAF-16/FOXO and EGL-27/GATA promote developmental growth in response to persistent somatic DNA damage
Michael M. Mueller et al.
NATURE CELL BIOLOGY (2014)
Transcription Restores DNA Repair to Heterochromatin, Determining Regional Mutation Rates in Cancer Genomes
Christina L. Zheng et al.
CELL REPORTS (2014)
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Giovanni Germano et al.
CANCER CELL (2013)
Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
Dan A. Landau et al.
CELL (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia
M. Sivina et al.
LEUKEMIA (2012)
Enhanced Nucleotide Excision Repair in Human Fibroblasts Pre-exposed to Ionizing Radiation
Patricia Cramers et al.
PHOTOCHEMISTRY AND PHOTOBIOLOGY (2012)
Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease
Alma Zecevic et al.
CLINICAL CANCER RESEARCH (2011)
Synergistic effects of combination with fludarabine and carboplatin depend on fludarabine-mediated inhibition of enhanced nucleotide excision repair in leukemia
Kazutaka Takagi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2011)
Cancer Selective Metallocenedicarboxylates of the Fungal Cytotoxin Illudin M
Rainer Schobert et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling
Mirza Suljagic et al.
BLOOD (2010)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Melanoma-specific ferrocene esters of the fungal cytotoxin illudin M
Sebastian Knauer et al.
ANTI-CANCER DRUGS (2009)
High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia
Marco Herling et al.
BLOOD (2009)
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Jan A. Burger et al.
BLOOD (2009)
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Persistent transcription-blocking DNA lesions trigger somatic growth attenuation associated with longevity
George A. Garinis et al.
NATURE CELL BIOLOGY (2009)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells
Alexandre E. Escargueil et al.
JOURNAL OF CELL SCIENCE (2008)
Age to survive: DNA damage and aging
Bjorn Schumacher et al.
TRENDS IN GENETICS (2008)
Multiple forms of nuclear p53 formed in human Raji and MEC1 cells treated with fludarabine
S. Henrich et al.
LEUKEMIA (2008)
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
Federica Grosso et al.
LANCET ONCOLOGY (2007)
Extreme sensitivity to Yondelis® (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53
Victoria Moneo et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia
Amy J. Johnson et al.
BLOOD (2006)
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response
A Rosenwald et al.
BLOOD (2004)
Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells
F Koeppel et al.
CLINICAL CANCER RESEARCH (2004)
Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent
MCS Herzig et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways
NGJ Jaspers et al.
DNA REPAIR (2002)
Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression
R Bichi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
Y Takebayashi et al.
NATURE MEDICINE (2001)
Genome maintenance mechanisms for preventing cancer
JHJ Hoeijmakers
NATURE (2001)
Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways
G Damia et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139
EP Rogakou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
